ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic...
Stryker delivered 9% organic sales growth in Q2 2026 with strength across MedSurg, Neurotechnology, and Orthopaedics, supported by expanding Mako robotics adoption. However, ongoing cybersecurity remediation costs, peripheral vascular supply disruptions, and tariff-related margin benefits complicate the outlook. The...
The global functional foods and beverages market is projected to grow from $365.1 billion in 2024 to $591.7 billion by 2030, with a CAGR of 8.6%. Growth is driven by consumer shift toward preventive health nutrition, premiumization, beverage innovation, and expansion in Asia-Pacific. North America leads with 34.3%...
The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share,...
The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for...
The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22.8% year-to-date in 2026, outperforming the S&P 500's 11.8% gain. The rotation toward value and dividend stocks is expected to continue due to inflation concerns, higher interest rates, strong corporate earnings growth, and shrinking valuations. The ETF's focus on...
Boston Scientific plans multiple product launches through 2028 across Interventional Cardiology, EP, and CRM segments, including SEISMIQ 4CE, FARAWAVE Ultra, and PRECEDENT platforms. However, the company expects flat global EP growth in H2 2026 due to competitive pressures, with momentum expected to return in H2 2027....
The article recommends three healthcare dividend stocks for long-term investors: Pfizer, Abbott Laboratories, and Medtronic. Despite recent challenges, all three companies offer strong dividend programs with growth potential. Pfizer has a promising pipeline including weight loss and cancer drugs. Abbott benefits from a...
Ken Griffin's Citadel hedge fund increased its AbbVie stake by over 500% in Q2 2026, signaling confidence in the pharmaceutical company's defensive qualities and dividend strength. AbbVie, a Dividend King with 50+ consecutive annual dividend increases, offers a 2.6% yield and has successfully navigated patent cliffs...
The in vitro diagnostics market is undergoing structural transformation, shifting from centralized laboratory testing to decentralized point-of-care platforms. Valued at $96.5 billion in 2026 and forecast to reach $140.4 billion by 2033 at 5.5% CAGR, the market is increasingly driven by molecular diagnostics,...
In a comparison of two Medical Products stocks, Envista (NVST) emerges as the superior value option over Abbott (ABT). NVST holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 17.51 and PEG ratio of 1.28. ABT has a Zacks Rank #3 (Hold) with a Value grade of C, with higher...
Medtronic (MDT) raised its fiscal 2027 revenue growth guidance to 7.25%-7.75% following a strong first quarter with adjusted EPS of $1.45 (up 15.1% YoY) and revenues of $9.76 billion (up 13.7%). The company's recent acquisitions in neurovascular and pain markets add exposure to faster-growing segments. However, margin...
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive...
Abbott Laboratories, a Dividend King with 54 consecutive years of dividend increases, is positioned as a defensive investment for potential market downturns. The company reported strong Q2 results with 13% sales growth and raised its full-year EPS guidance. With a 46% payout ratio and growth catalysts from medical...
Novocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no...
The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 57% total return over three years and is recommended as a strong buy for income-focused investors seeking stability and diversification. While the fund offers solid dividend growth (7.53% annually) and exposure to mature, profitable companies, its limited tech...
Schwab U.S. Dividend Equity ETF (SCHD) offers nearly double the dividend yield of Vanguard Dividend Appreciation ETF (VIG) at 3% versus 1.5%, with a value-focused portfolio in healthcare and consumer defensives. VIG emphasizes technology stocks and requires 10-year dividend growth streaks. SCHD showed stronger one-year...
The global Baby Food and Infant Formula Market was valued at USD 40.37 billion in 2025 and is projected to reach USD 74.30 billion by 2035, growing at a CAGR of 6.29%. Growth is driven by urbanization, increasing parental health consciousness, demand for organic/premium products, and e-commerce expansion. However,...
The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while...
The Invesco Pharmaceuticals ETF (PJP) is a passively managed fund tracking the Dynamic Pharmaceutical Intellidex Index with $541.13 million in assets. It offers broad exposure to U.S. pharmaceutical companies with a 0.57% expense ratio and 0.82% dividend yield. The ETF has gained 24.96% year-to-date and 41.74% over the...
Headlines via Polygon.io. Links open the original publisher.